A prospective phase II trial of vinorelbine plus oxaliplatin in second- or third-line metastatic triple-negative breast cancer

被引：0
|
作者：
Wang, Z. [1 ]
Zhang, J. [1 ]
Wang, L. [1 ]
Hu, X. [1 ]
Wang, B. [1 ]
Cao, J. [1 ]
Lv, F. [1 ]
Zhen, C. [1 ]
Zhang, S. [1 ]
Shao, Z. [1 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai 200433, Peoples R China
来源：
CANCER RESEARCH | 2013年 / 73卷
关键词：
D O I：
10.1158/0008-5472.SABCS13-P3-13-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-13-06
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II trial of biweekly vinorelbine and oxaliplatin in second-or third-line metastatic triple-negative breast cancer
    Zhang, Jian
    Wang, Leiping
    Wang, Zhonghua
    Hu, Xichun
    Wang, Biyun
    Cao, Jun
    Lv, Fangfang
    Zhen, Chunlei
    Zhang, Sheng
    Shao, Zhimin
    CANCER BIOLOGY & THERAPY, 2015, 16 (02) : 225 - 232
  • [2] Second- and third-line treatment of metastatic breast cancer with gemcitabine
    Brodowicz, T
    Möslinger, R
    Herscovici, V
    Vaclavik, I
    Wiltschke, C
    Kubista, E
    Zielinski, C
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S44 - S44
  • [3] Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial
    Li, Dou-Dou
    Tao, Zhong-hua
    Wang, Bi-Yun
    Wang, Lei-Ping
    Cao, Jun
    Hu, Xi-Chun
    Zhang, Jian
    NPJ BREAST CANCER, 2022, 8 (01)
  • [4] Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial
    Dou-Dou Li
    Zhong-hua Tao
    Bi-Yun Wang
    Lei-Ping Wang
    Jun Cao
    Xi-Chun Hu
    Jian Zhang
    npj Breast Cancer, 8
  • [5] Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer
    Bendell, Johanna C.
    Nemunaitis, John
    Vukelja, Sasha J.
    Hagenstad, Christopher
    Campos, Luis T.
    Hermann, Robert C.
    Sportelli, Peter
    Gardner, Lesa
    Richards, Donald A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (33) : 4394 - 4400
  • [6] Phase II trial of RAMO I plus carhoplatin in patients with triple-negative metastatic breast cancer
    Singh, J. C.
    Stein, S.
    Volm, M.
    Smith, J. A.
    Novik, Y.
    Speyer, J. L.
    Adams, S.
    Meyers, M. I.
    Muggia, F.
    Schneider, R.
    Formenti, S.
    Davis, S.
    Choi, H.
    Tiersten, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [7] Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program
    Cabel, Luc
    Carton, Matthieu
    Pistilli, Barbara
    Dalenc, Florence
    Vanlemnens, Laurence
    Levy, Christelle
    Jacot, William
    Debled, Michel
    Loeb, Agnes
    Hennequin, Audrey
    Rouge, Thibault De la Motte
    Laborde, Lilian
    Laurent, Carine
    Chamorey, E.
    Parent, Damien
    Petit, Thierry
    Mouret-Reynier, Marie-Ange
    Campone, Mario
    Perrocheau, Genevieve
    Labreveux, Claire
    Bachelot, Thomas
    Robain, Mathieu
    Lerebours, Florence
    BREAST, 2021, 56 : 18 - 25
  • [8] A phase II study of ganetespib (G) as second- or third-line therapy for metastatic pancreatic cancer (MPC).
    Thota, Ramya
    Goff, Laura Williams
    Chan, Emily
    Berlin, Jordan
    Jones, C. Michael
    McClanahan, Pamela
    Ayers, Gregory Dan
    Cardin, Dana Backlund
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [9] A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer
    Goncalves, A.
    Fabbro, M.
    Lhomme, C.
    Gladieff, L.
    Extra, J. -M.
    Floquet, A.
    Chaigneau, L.
    Carrasco, A. Tisseron
    Viens, P.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (01) : 42 - 46
  • [10] Amrubicin as second- or third-line treatment for patients with HER2-negative metastatic breast cancer (MBC): A phase II trial of the Sarah Cannon Research Institute (SCRI)
    Barton, John H.
    Raefsky, Eric
    Harwin, William N.
    Inclan, Alejandro A.
    Miletello, Gerald
    Hainsworth, John D.
    Burris, Howard A.
    Yardley, Denise Aysel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345